AIM ImmunoTech Inc. (AIM)
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $88.0K
- Net income
- -$14.0M
- Total assets
- $5.8M
- Market cap
- $7.5M
- Operating margin
- -13254.5%
- Net margin
- -15861.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $88.0K
- Operating expenses
- $11.8M
- Operating income
- -$11.7M
- Net income
- -$14.0M
- EPS (basic)
- $-8.62
- EPS (diluted)
- $-8.62
Balance sheet
- Total assets
- $5.8M
- Current assets
- $3.3M
- Total liabilities
- $15.6M
- Current liabilities
- $6.2M
- Shareholders’ equity
- -$9.8M
Cash flow
- Operating cash flow
- -$11.0M
- Investing cash flow
- $1.9M
- Financing cash flow
- $10.4M
- Net cash flow
- $1.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $7.5M
- EPS (diluted)
- $-8.62
- Shares outstanding
- 28.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 2, 1995
AIM ImmunoTech Inc. (AIM) Stock Price
- Reported a net loss of $14.0M in FY2025.
- Revenue declined 35% from FY2021 to FY2025.
- Trading 97% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review AIM ImmunoTech Inc..
Write a review
News about AIM ImmunoTech Inc.
News & sentiment via Polygon.io
AIM ImmunoTech Inc.: frequently asked questions
Is AIM ImmunoTech Inc. an American company?
AIM ImmunoTech Inc. is a US-based company headquartered in Ocala, Florida, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is AIM ImmunoTech Inc. headquartered?
AIM ImmunoTech Inc. is headquartered in Ocala, Florida, United States.
Is AIM ImmunoTech Inc. publicly traded?
Yes — AIM ImmunoTech Inc. is a publicly traded company. Its stock trades under the ticker symbol AIM on the NYSE.
What does AIM ImmunoTech Inc. do?
AIM ImmunoTech Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
